IGI Logo

Zydus Lifesciences is currently trading at Rs. 483.15, up by 0.80 points or 0.17% from its previous closing of Rs. 482.35 on the BSE.

The scrip opened at Rs. 480.35 and has touched a high and low of Rs. 483.40 and Rs. 478.65 respectively. So far 11881 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022.

Last one week high and low of the scrip stood at Rs. 485.75 and Rs. 469.00 respectively. The current market cap of the company is Rs. 48838.85 crore.

The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 16.21% and 8.81% respectively.
 
Zydus Lifesciences has received final approval for Doxepin Hydrochloride Capsules USP, 150 mg (USRLD: Sinequan Capsules) from the United States Food and Drug Administration (USFDA).

Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety. It helps improve moods and feelings of well-being, relieves anxiety and tension, helps sleep better and increases the energy level. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).

Doxepin Hydrochloride Capsules USP, 150 mg had annual sales of $2.11 million in the United States (IQVIA MAT Jan. 2023). The group now has 353 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.